From a clinical point of view, it is therefore important to determine whether torasemide and spironolactone, the classical mineralocorticoid receptor antagonist (MRA), have similar targets and whether these drugs should be associated to potentiate their efficacy in the treatment of HF. This evidence concerns the gene NR3C2 and hydrops fetalis.